Insmed

Brinsupri
Pharma

Insmed's Brinsupri comes up short in rhinosinusitis trial

Insmed's shares tumbled by 16% when it reported the failure of a phase 2 trial of Brinsupri in chronic rhinosinusitis without nasal polyps.
Lung Fibrosis

United shares surge on Tyvaso win in new lung disease population

Sep 2, 2025 3:34pm
Brinsupri

Insmed's Brinsupri nabs landmark FDA nod in chronic lung disease

Aug 12, 2025 12:05pm
Arrows hitting targets

Insmed's phase 2 PAH win sends stock soaring

Jun 10, 2025 11:59am
drug launch

Top 10 most anticipated drug launches of 2025

Jan 27, 2025 3:00am
Sketch of lungs

Jane Seymour backs Insmed's push to tackle gender and age biases

Mar 5, 2024 6:41am